SR-9011

Overview

SR-9011 is a synthetic small-molecule REV-ERB (Rev-erbα/β) agonist — not a peptide — studied preclinically as a circadian and metabolic modulator. It has no human data, no regulatory approval, and is WADA-prohibited at all times. It is commonly confused with "Stenabolic," which is properly its analog SR9009, not SR-9011.

Mechanism of Action

SR-9011 is an agonist of REV-ERBα and REV-ERBβ. Binding enhances REV-ERB-mediated transcriptional repression (recruiting the NCoR corepressor), repressing core clock genes such as Bmal1 and downstream metabolic genes in liver, muscle, and adipose (Solt et al., Nature 2012). All data are cellular or rodent.

Research Summary

In diet-induced obese mice (intraperitoneal dosing), SR-9011/SR9009 increased energy expenditure, reduced fat mass, and improved dyslipidemia and hyperglycemia (Solt et al., Nature 2012). Human liver microsome work identified 14 metabolites but no half-life, and the authors caution against human extrapolation. There are no registered human trials of SR-9011; no human safety, dose, or pharmacokinetic data exist.

Vendors selling SR-9011

Scored vendors carrying SR-9011, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• No human safety data — SR-9011 has never been tested in humans
• In-vitro data show suppressed immune cytokine expression and mitochondrial ATP production (rat microglia) — a mechanistic signal, not a demonstrated human effect
• WADA-prohibited at all times (S4.4.1, Rev-erbα agonists named explicitly)
• Gray-market products are unregulated with no independent purity verification

Compare SR-9011 with Others

Research References

• Solt LA, et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature. 2012. PMID 22460951.
• In vitro metabolic studies of REV-ERB agonists SR9009 and SR9011. Int J Mol Sci. 2016. PMID 27605625.
• Sulli G, et al. Pharmacological activation of REV-ERBs is lethal in cancer. Nature. 2018. PMID 29320480.

Frequently asked questions

Has SR-9011 been independently lab-tested?

Disclosed Labs has collected 1 Certificate of Analysis (COA) for SR-9011 from 1 independent testing lab. 1 vendor has submitted material for testing. Products average 96.8% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/sr-9011/testing.

Where can researchers source SR-9011?

1 vendor with Disclosed Labs trust grades currently list SR-9011, including Kimera Chems. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/sr-9011.

How does SR-9011 work?

SR-9011 is an agonist of REV-ERBα and REV-ERBβ. Binding enhances REV-ERB-mediated transcriptional repression (recruiting the NCoR corepressor), repressing core clock genes such as Bmal1 and downstream metabolic genes in liver, muscle, and adipose (Solt et al., Nature 2012). All data are cellular or rodent.

What does the research say about SR-9011?

In diet-induced obese mice (intraperitoneal dosing), SR-9011/SR9009 increased energy expenditure, reduced fat mass, and improved dyslipidemia and hyperglycemia (Solt et al., Nature 2012). Human liver microsome work identified 14 metabolites but no half-life, and the authors caution against human extrapolation. There are no registered human trials of SR-9011; no human safety, dose, or pharmacokinetic data exist.